HYPERION DEFI INC (HYPD)
NASDAQHealth CareAsset Management - CryptocurrencySnapshot 2026-09-14
$3.64+4.30%
Close 2026-09-14 · 1-day change
NASDAQHealth CareAsset Management - CryptocurrencySnapshot 2026-09-14
Research Workspace
Put HYPD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisManagement screens strong on capital allocation, the balance sheet.
View ManagementThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 84% in its worst 12-month stretch.
View RiskHYPD's growth in Adjusted Gross Profit and DeFi operating businesses must continue to justify its price. Revenue performance has been strong, with recent guidance raising expectations. HYPD trades at 65× price-to-sales, well above the peer median of 12×. This suggests the price is roughly in line with the growth we forecast. A specific risk is the potential for HYPD to cut guidance, which could negatively impact the stock. Peer multiples imply a price about 5% below where it trades. Our read is provisional.
Trailing returns as of 2026-09-14. HYPD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 2 analysts currently covering HYPD (as of Sep 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare HYPD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HYPD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across our valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No fair value published
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
This applies to all three horizons. The trailing multiples, peer comparison, and quality and trajectory reads on this page are unaffected. Names move in and out of this state day to day as the methods converge or diverge. Method agreement on this name is low.
Top 10% on quality vs scored peers
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put HYPD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Price target increase suggests positive outlook for growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Grow Adjusted Gross Profit and DeFi operating businesses
Increased profit guidance supports growth objectives.
Advances: Grow Adjusted Gross Profit and DeFi operating businesses
Outlines specific profit goals aligning with growth objectives.
Advances: Achieve positive Adjusted Net Operating Cash Flow by end of 2026
Earnings call discusses timeline for positive cash flow.
Advances: Grow Adjusted Gross Profit and DeFi operating businesses
Earnings call highlights strategic pivot supporting growth objectives.
Threatens: Grow Adjusted Gross Profit and DeFi operating businesses
Earnings beat but revenue shortfall raises growth concerns.
Advances: Cease support for USDH stablecoin
Expansion of staking infrastructure supports product development.